title: A randomised clinical trial to assess control of oral malodour by a novel dentifrice containing 0.1%w/w o-cymen-5-ol, 0.6%w/w zinc chloride.
abstract: OBJECTIVE
  To assess the ability of a 0.1% w/w o-cymen-5-ol/ 0.6% w/w zinc chloride/ sodium fluoride dentifrice to control oral malodour compared to a sodium fluoride control dentifrice.
  
  
  METHODS
  Following baseline measurement of oral volatile sulfur compounds (VSCs), the subjects brushed twice daily for 1 week with either the test or control dentifrice. The VSC concentration in breath samples was monitored up to 12 hours post-treatment, by gas chromatography (GC).
  
  
  RESULTS
  75 subjects were included in the efficacy analysis. Relative to the sodium fluoride control dentifrice group the o-cymen-5-ol/ zinc chloride/ sodium fluoride dentifrice exhibited statistically significant reductions (P<0.0001) in hydrogen sulfide, methyl mercaptan and total measured VSCs immediately and after 1, 2, 3 and 12 (overnight) hours post-treatment.
  
  
  CONCLUSIONS
  The results of the present clinical study demonstrated that the use of the 0.1% w/w o-cymen-5-ol/ 0.6% w/w zinc chloride/ sodium fluoride dentifrice over a one week period provided a statistically significant benefit in controlling oral malodour for up to 12 hours post-treatment compared to a sodium fluoride control dentifrice.
authors.affiliation: Intertek 4-Front Research, Ellesmere Port, UK GlaxoSmithKline Consumer Healthcare, Weybridge, Surrey, UK.
authors.forename: David
authors.initials: D
authors.lastname: Payne
authors.forename: Jenny J
authors.initials: JJ
authors.lastname: Gordon
authors.forename: Stephanie
authors.initials: S
authors.lastname: Nisbet
authors.forename: Ritu
authors.initials: R
authors.lastname: Karwal
authors.forename: Mary Lynn
authors.initials: ML
authors.lastname: Bosma
mesh_terms: D001944:Breath Tests; D002712:Chlorides / Q000627:therapeutic use*; D002849:Chromatography, Gas / Q000379:methods; D018592:Cross-Over Studies; D003802:Dentifrices / Q000737:chemistry / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006209:Halitosis / Q000517:prevention & control*; D006801:Humans; D006862:Hydrogen Sulfide / Q000032:analysis; D008297:Male; D008875:Middle Aged; D010636:Phenols / Q000627:therapeutic use*; D012969:Sodium Fluoride / Q000627:therapeutic use; D013438:Sulfhydryl Compounds / Q000032:analysis; D017967:Zinc Compounds / Q000627:therapeutic use*
chemical_list: D002712:Chlorides; D003802:Dentifrices; D010636:Phenols; D013438:Sulfhydryl Compounds; D017967:Zinc Compounds; C005231:methylmercaptan; C016837:zinc chloride; D012969:Sodium Fluoride; C512394:o-cymen-5-ol; D006862:Hydrogen Sulfide